# Apimeds Pharmaceuticals US, Inc. (APUS)

> Source: Nexqual · https://nexqual.com/APUS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Apimeds Pharmaceuticals US, Inc. (APUS), nexqual.com/APUS" · informational, not investment advice.

**Price:** USD 4.39 (-4.15% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.58 · day 4.01–4.41 · 52w 1.51–59.7 · market cap $6.6M · ASE

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -76.1% vs S&P 500 +18.1%; 5Y -80.0% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Operating income | -$747K | -$1.3M | -$11.9M | -$27.3M |
| Net income | -$778K | -$1.4M | -$6.0M | -$58.2M |
| EPS (diluted) | -$1.70 | -$1.80 | -$5.50 | — |
| Free cash flow | — | — | -$9.0M | -$13.3M |
| Cash + short-term investments | $410K | $3K | $3.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.1x · FCF yield -201.25% · Earnings yield -878.03%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2025-05-05) |
|---|---|---|
| Total return | -76.1% | -80.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -76.3% | -67.2% |
| Volatility (annualized) | 190.6% | 179.6% |
| Max drawdown | -95.9% (Nov 2025→Sep 2026) | -94.5% (Nov 2025→Sep 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 39.57 -5.81% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/APUS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt